Klin Padiatr 2020; 232(02): 89
DOI: 10.1055/s-0040-1701843
PW I-V
Guided Poster Walk
© Georg Thieme Verlag KG Stuttgart · New York

Comparative proteomic profiling in recurrent pediatric/adolescent Hodgkin Lymphoma

O Repetto
1   Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Immunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Aviano, Italy
,
L Mussolin
2   University of Padova, Department of Women’s and Children’s Health, Padova, Italy
3   Istituto di Ricerca Pediatrica Città della Speranza, Unit of Onco-hematology, stem cell transplant and gene therapy, Padova, Italy
,
C Elia
4   Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Pediatric Radioterapy Unit, Padova, Italy
,
L Caggiari
1   Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Immunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Aviano, Italy
,
M De Zorzi
1   Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Immunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Aviano, Italy
,
A Garbin
2   University of Padova, Department of Women’s and Children’s Health, Padova, Italy
3   Istituto di Ricerca Pediatrica Città della Speranza, Unit of Onco-hematology, stem cell transplant and gene therapy, Padova, Italy
,
C Diamanti
2   University of Padova, Department of Women’s and Children’s Health, Padova, Italy
3   Istituto di Ricerca Pediatrica Città della Speranza, Unit of Onco-hematology, stem cell transplant and gene therapy, Padova, Italy
,
I Gallingani
2   University of Padova, Department of Women’s and Children’s Health, Padova, Italy
3   Istituto di Ricerca Pediatrica Città della Speranza, Unit of Onco-hematology, stem cell transplant and gene therapy, Padova, Italy
,
M Bianchi
5   Regina Margherita Children’s Hospital, Pediatric Onco-Hematology and Stem Cell Transplant Division, City of Health and Science, Torino, Italy
,
S Buffardi
6   Paediatric Haemato-Oncology department, Santobono-Pausilipon Children’s Hospital, Napoli, Italy
,
A Sala
7   Department of Paediatrics, Ospedale San Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy
,
R Burnelli
8   Sant’Anna Hospital Pediatric Oncology, Pediatric Oncology University Hospital, Ferrara, Italy
,
E Facchini
9   Department of Pediatrics, University of Bologna, Sant’Orsola-Malpighi Hospital, Bologna, Italy
,
M Mascarin
4   Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Pediatric Radioterapy Unit, Padova, Italy
,
V De Re
1   Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Immunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Aviano, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2020 (online)

Also available at
 
 

Introduction Inpediatric/adolescent Hodgkin lymphoma (HL) the discovery of protein(s) specifically associated with the presence/absence of relapse may contribute to optimize therapeutic approaches.

Methods Liquid chromatography-mass spectrometry (LC-MS) label-free quantitative proteomics on plasma collected at diagnosis from pediatric/adolescent HL patients was adopted firstly to validate a set of biomarkers predicting disease relapse, and secondly to identify additional candidate protein panels for disease relapse. Protein profiles of 3 not relapsing (NR) HL patients were compared with those of 3 relapsing (R) ones treated with LH-2004 protocol in one ‘explorative’ and two ‘validation’ cohorts.

Results The LC-MS approach validated some differential proteins we previously identified by Differential In Gel Electrophoresis (SERPINC1, SERPINA1, FGB and FGG) [1]. In each protein group belonging to either NR or R patients, bioinformatics functional enrichments showed several biological processes, which were manually grouped into 9 ‘biological classes’. The differential proteins were involved in several biological processes related to either the absence (e.g., regulation of protein metabolism, response and haemostasis) or the presence of relapse (e.g., immune system and cell and extra-cellular matrix architecture). Moreover, additional proteins were found as up-regulated in either NR or R plasma of HL patients, and data were validated with Western Blotting.

Conclusion Overall, our data depict a part of the different molecular scenarios occurring at diagnosis in plasma of HL pediatric/adolescent patients that could affect their different responses to therapy, and provide new evidence about these protein panels as promising biomarkers of relapse in HL pediatric/adolescent disease. Further studies are underway in the EURONET-PHL trial of pediatric/adolescent patients.


#

  • References

  • 1 Repetto O, Mussolin L, Elia C, Martina L, Bianchi M, Buffardi S, Sala A, Burnelli R, Mascarin M, De Re V. 2018; . Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma. Journal of Cancer. 9: 4650-4658.
    CrossrefPubMedGoogle Scholar

  • References

  • 1 Repetto O, Mussolin L, Elia C, Martina L, Bianchi M, Buffardi S, Sala A, Burnelli R, Mascarin M, De Re V. 2018; . Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma. Journal of Cancer. 9: 4650-4658.
    CrossrefPubMedGoogle Scholar